HK1090571A1 - Methods for preventing mitochondrial permeability transition - Google Patents

Methods for preventing mitochondrial permeability transition

Info

Publication number
HK1090571A1
HK1090571A1 HK06112161.2A HK06112161A HK1090571A1 HK 1090571 A1 HK1090571 A1 HK 1090571A1 HK 06112161 A HK06112161 A HK 06112161A HK 1090571 A1 HK1090571 A1 HK 1090571A1
Authority
HK
Hong Kong
Prior art keywords
methods
permeability transition
mitochondrial permeability
preventing mitochondrial
preventing
Prior art date
Application number
HK06112161.2A
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Priority to HK09110947.4A priority Critical patent/HK1131995A1/xx
Publication of HK1090571A1 publication Critical patent/HK1090571A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
HK06112161.2A 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition HK1090571A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08
PCT/US2004/003193 WO2004070054A2 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Publications (1)

Publication Number Publication Date
HK1090571A1 true HK1090571A1 (en) 2006-12-29

Family

ID=32853391

Family Applications (6)

Application Number Title Priority Date Filing Date
HK06112161.2A HK1090571A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition
HK14104163.7A HK1190930A1 (en) 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Family Applications After (5)

Application Number Title Priority Date Filing Date
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition
HK14104163.7A HK1190930A1 (en) 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Country Status (14)

Country Link
US (8) US7576061B2 (ja)
EP (9) EP2865385B1 (ja)
JP (7) JP4838114B2 (ja)
CN (3) CN104225574B (ja)
AU (1) AU2004209663B2 (ja)
CA (1) CA2515080C (ja)
CY (2) CY1114959T1 (ja)
DK (3) DK1599216T3 (ja)
ES (3) ES2540897T3 (ja)
HK (6) HK1090571A1 (ja)
HU (1) HUE027110T2 (ja)
PT (2) PT1599216E (ja)
SI (1) SI2656854T1 (ja)
WO (1) WO2004070054A2 (ja)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865385B1 (en) 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
JP4931604B2 (ja) * 2004-01-23 2012-05-16 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
US7541340B2 (en) * 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
ES2458870T3 (es) 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
DE102008061044A1 (de) 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
EP3292868A1 (en) 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
EP3120860B1 (en) * 2009-10-05 2019-06-26 Cornell University Methods for the prevention or treatment of cardiac fibrosis
WO2011082328A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CA2786280A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
JP2013522311A (ja) * 2010-03-15 2013-06-13 ステルス ペプチドズ インターナショナル インコーポレイテッド シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法
US20110245183A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP2942354A1 (en) * 2010-05-03 2015-11-11 Stealth Peptides International, Inc. Aromatic-Cationic Peptides and Uses of Same
CN105879008A (zh) * 2010-07-09 2016-08-24 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
JP2014520246A (ja) * 2011-03-24 2014-08-21 コーネル ユニヴァーシティー 芳香族カチオン性ペプチド及びその使用
EP2758411A2 (en) * 2011-09-19 2014-07-30 Gencia Corporation Modified creatine compounds
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CN104114181B (zh) * 2011-10-17 2017-06-09 康奈尔大学 芳香族阳离子肽及其用途
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3170506B1 (en) 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
EP3132800A1 (en) * 2012-08-02 2017-02-22 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
KR20160009008A (ko) * 2012-10-22 2016-01-25 스텔스 바이오테라퓨틱스 코포레이션 심부전과 관련된 위험 및 이와 관련된 인자를 감소시키는 방법
EP2961378B1 (en) * 2013-03-01 2019-10-23 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015017861A1 (en) 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
CN106163537A (zh) * 2013-09-30 2016-11-23 康奈尔大学 心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
WO2016069556A2 (en) 2014-10-29 2016-05-06 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
CN109563131A (zh) 2016-04-11 2019-04-02 卡诺有限责任公司 手性肽
JP6427691B2 (ja) 2016-11-30 2018-11-21 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
EP3606938A1 (en) 2017-04-05 2020-02-12 Stealth BioTherapeutics Corp Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
CN115109116A (zh) 2017-08-17 2022-09-27 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂衍生物的制备及用途
ES2947741T3 (es) 2017-09-04 2023-08-17 Xwpharma Ltd Preparación y uso de un barredor de especies reactivas de oxígeno
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
JP2022511939A (ja) * 2018-12-18 2022-02-01 ステルス バイオセラピューティクス コーポレーション ミトコンドリア標的化ペプチド
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation THERAPEUTIC AND PROPHYLACTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE68926269T2 (de) 1988-06-30 1996-08-14 Astra Ab Dermorphin-Analoge, deren Herstellungsverfahren, pharmazeutische Zusammensetzungen und Methode zur therapeutischen Behandlung unter Verwendung der Analoge
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
WO1991010361A1 (en) * 1990-01-17 1991-07-25 The Regents Of The University Of California Composition to improve survival of biological materials
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
EP0971709B1 (en) * 1996-10-07 2003-05-21 Eli Lilly And Company Novel compounds useful as neuro-protective agents
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
EP1218544B1 (en) * 1999-10-04 2009-06-03 The University of Medicine and Dentistry of New Jersey TAR RNA binding peptides
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
JP2004523490A (ja) * 2000-11-28 2004-08-05 ギルフォード ファーマシュウティカルズ インコーポレイテッド 二置換カルボサイクリックサイクロフィリン結合化合物とその用途
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
US6656971B2 (en) * 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2002066096A2 (en) * 2001-02-16 2002-08-29 Cordis Corporation Balloon catheter stent delivery system with ridges
WO2002074194A2 (en) * 2001-03-16 2002-09-26 Sts Biopolymers, Inc. Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
SI1599216T1 (sl) * 2003-02-04 2014-02-28 Cornell Research Foundation, Inc. Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
JP4931604B2 (ja) * 2004-01-23 2012-05-16 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
US7541340B2 (en) 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression

Also Published As

Publication number Publication date
US20120021970A1 (en) 2012-01-26
JP2013249313A (ja) 2013-12-12
JP6166312B2 (ja) 2017-07-19
US20230293624A1 (en) 2023-09-21
JP2019089773A (ja) 2019-06-13
US20070027087A1 (en) 2007-02-01
HK1209652A1 (en) 2016-04-08
CA2515080A1 (en) 2004-08-19
EP1599216B9 (en) 2015-02-11
US20200038472A1 (en) 2020-02-06
WO2004070054A3 (en) 2005-04-14
EP1599216A2 (en) 2005-11-30
JP5775285B2 (ja) 2015-09-09
HK1204999A1 (en) 2015-12-11
EP2656854B1 (en) 2015-05-20
EP3479838A1 (en) 2019-05-08
US7718620B2 (en) 2010-05-18
DK2656854T3 (en) 2015-07-06
US20150359838A1 (en) 2015-12-17
HK1190930A1 (en) 2014-07-18
JP5837542B2 (ja) 2015-12-24
EP1599216B1 (en) 2013-11-06
JP2015007127A (ja) 2015-01-15
CN102784383A (zh) 2012-11-21
JP2011026346A (ja) 2011-02-10
DK2865385T3 (en) 2016-12-19
EP3305313A1 (en) 2018-04-11
US20130244957A1 (en) 2013-09-19
WO2004070054A2 (en) 2004-08-19
DK1599216T3 (da) 2013-12-09
ES2540897T3 (es) 2015-07-14
EP1599216A4 (en) 2009-11-11
US7576061B2 (en) 2009-08-18
JP2015180693A (ja) 2015-10-15
AU2004209663B2 (en) 2009-01-15
AU2004209663A2 (en) 2004-08-19
CN102617706A (zh) 2012-08-01
EP2865385A1 (en) 2015-04-29
PT2656854E (pt) 2015-09-03
JP6126059B2 (ja) 2017-05-10
SI2656854T1 (sl) 2015-09-30
US20100190718A1 (en) 2010-07-29
EP2491943B1 (en) 2018-10-10
EP2656854A1 (en) 2013-10-30
JP4838114B2 (ja) 2011-12-14
JP2017095519A (ja) 2017-06-01
CN102784383B (zh) 2014-09-17
US8404646B2 (en) 2013-03-26
HK1178794A1 (en) 2013-09-19
HUE027110T2 (en) 2016-08-29
EP2865385B1 (en) 2016-11-16
CA2515080C (en) 2012-04-10
US8957030B2 (en) 2015-02-17
EP2491943A3 (en) 2013-01-23
EP3659618A1 (en) 2020-06-03
CN104225574A (zh) 2014-12-24
ES2605504T3 (es) 2017-03-14
CN104225574B (zh) 2017-01-11
EP3842055A1 (en) 2021-06-30
CY1114959T1 (el) 2016-12-14
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
EP3144009A1 (en) 2017-03-22
JP2006516652A (ja) 2006-07-06
AU2004209663A1 (en) 2004-08-19
PT1599216E (pt) 2013-12-17
ES2436011T3 (es) 2013-12-26
US20040248808A1 (en) 2004-12-09
CY1116575T1 (el) 2017-03-15

Similar Documents

Publication Publication Date Title
HK1204999A1 (en) Methods for preventing mitochondrial permeability transition
GB2401643B (en) Padlock
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
GB0326439D0 (en) Methods
AU155985S (en) Beaker
SI1599216T1 (sl) Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
PT1706373E (pt) Derivados de amidoacetonitrilo
GB0328243D0 (en) Methods
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0327909D0 (en) Methods
GB0320627D0 (en) Methods
GB0327368D0 (en) Methods
GB0315827D0 (en) Methods
GB0307076D0 (en) Methods
GB0328747D0 (en) Methods
GB0323793D0 (en) Methods
GB0305252D0 (en) Methods
AU2003280821A8 (en) Beauveriolide derivative
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
GB0329560D0 (en) Methods

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240202